Suppr超能文献

通过宫颈内应用一种新型硫前列酮凝胶进行术前宫颈预处理。

Preoperative cervical priming by intracervical application of a new sulprostone gel.

作者信息

Rath W, Dennemark N, Gödicke H D

出版信息

Contraception. 1985 Mar;31(3):207-16. doi: 10.1016/0010-7824(85)90091-5.

Abstract

In a prospective, randomised dose-finding study involving 60 women scheduled for termination of 1st trimester pregnancy, 25 micrograms, 50 micrograms or 100 micrograms of a sulprostone gel with a constant injection volume of 2.5 ml were applied intracervically 6-8 hours before curettage. The gelatinising agent was Pluronic F 127, which is liquid at temperatures less than 20 degrees C but gelatinises immediately at body temperature. A sterile, ready-to-use gel can be produced within a minute by mixing the active substance with the gelatinising agent; this rules out any loss of activity due to storage of the substances. The priming effect was verified in 30 patients by means of comparative examinations with a special tonometer before application of the gel and immediately before the surgical procedure. The 100-micrograms dosage proved to be the most effective method in nulliparae, achieving a mean free patency (i.e. force less than 1 Newton) of 8.7 mm. In primiparae and multiparae, a comparable good effect was achieved with the 50-micrograms dose. After application of 25 micrograms sulprostone gel, the mean free patency was only 5.3 mm in the nulliparae and 8.5 mm in the primiparae and multiparae. The results of the tonometric studies agreed with the clinical documentation of the priming effect, which was assessed by means of a special score. The efficiency of the cervical priming correlated with the rate of vaginal bleeding and with the frequency of contraction-related lower abdominal pain. According to the present results, local application of this sulprostone gel represents a practicable and promising method for preoperative cervical priming because of its special electromechanical properties.

摘要

在一项前瞻性随机剂量探索研究中,60名计划终止早期妊娠的女性参与其中,在刮宫术前6 - 8小时,将2.5毫升恒定注射体积、含25微克、50微克或100微克硫前列酮的凝胶经宫颈给药。凝胶化剂为普朗尼克F127,其在低于20摄氏度时为液体,但在体温下会立即凝胶化。将活性物质与凝胶化剂混合,一分钟内即可制成无菌即用型凝胶;这排除了因物质储存导致的活性丧失。在30名患者中,通过在凝胶给药前和手术即将开始前使用特殊眼压计进行对比检查,验证了预扩张效果。结果显示,100微克剂量对未产妇最为有效,平均自由通畅度(即力小于1牛顿)达到8.7毫米。对于初产妇和经产妇,50微克剂量可取得类似的良好效果。应用25微克硫前列酮凝胶后,未产妇的平均自由通畅度仅为5.3毫米,初产妇和经产妇为8.5毫米。眼压测量研究结果与通过特殊评分评估的预扩张效果的临床记录一致。宫颈预扩张的效果与阴道出血率以及与宫缩相关的下腹部疼痛频率相关。根据目前的结果,由于其特殊的机电特性,局部应用这种硫前列酮凝胶是术前宫颈预扩张的一种可行且有前景的方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验